RNS Number: 7835 I Faron Pharmaceuticals Oy 03 April 2020 Faron Pharmaceuticals Oy. Company announcement, 3 April 2020 at 4.45 pm. TURKU, FINLAND- Faron Pharmaceuticals Oy, the clinical stage biopharmaceutical company, today announces that, due to the prevailing Covid-19 situation, the Company's Board of Directors has decided to cancel the Company's annual...
Faron Pharmaceuticals #FARN Inclusion of Traumakine in pneumonia trial Share price: 470p; Market Capitalisation: £203m Finnish drug developer, Faron Pharma, notes the regulatory approval for a global multicentre trial evaluating treatment options for community-acquired pneumonia including COIVD-19 patients. The trial, known as REMAP-CAP aims to recruit 6,800 patients and evaluate multiple treatment modalities, from antibiotics to hydrocortisone (link to trial website). The trial will include the use of Traumakine, Faron’s interferon-based treatment candidate. Traumakine, an intravenous interferon beta-1a (IFN-β) treatment is to be used in part of the trial testing test the use of interferon on the clinical outcomes of COVID-19 patients and those with other causes of pneumonia requiring ICU care Whilst smaller trials are providing anecdotal data about the efficacy of existing treatments against COVID-19, larger studies such as REMAP-CAP and the SOLIDARITY trial being performed by the World Health Organisation should provide further guidance as to the efficacy of therapies against COVID-19. In 2018, Traumakine failed a Phase 3 trial (INTEREST) in acute respiratory distress syndrome (ARDS). It was suggested that standard-of-care corticosteroids were impacting the efficacy of Traumakine. The REMAP-CAP trial should provide further data on this observation. IFN-β is a cytokine protein involved in the body’s antiviral responses as part of the innate immune system. Coronaviruses, such as SARS-CoV-2, have mechanisms to suppress IFN- β production to evade the body’s immune system. A deficiency in IFN-β production by the lung may explain why certain patients develop severe lung diseases during respiratory viral infections, such as COVID-19. Elsewhere on AIM, Synairgen (SNG.L*), a respiratory drug development company, commenced dosing of patients for its trial of SNG001 (inhaled formulation of IFN-β1a) in COVID-19 patients. *One of the authoring analysts has an interest in Synairgen shares
RNS Number: 3681 I Faron Pharmaceuticals Oy 01 April 2020 Faron Pharmaceuticals Oy. TURKU- FINLAND- Faron Pharmaceuticals Oy, the clinical stage biopharmaceutical company, announces today that regulatory approval has been granted for the global Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community-Acquired Pneumonia program that...
RNS Number: 9602 H Faron Pharmaceuticals Oy 30 March 2020 Faron Pharmaceuticals Oy. Completion of Part 1 dose finding stage of the MATINS Phase I/II Study. TURKU- FINLAND- Faron Pharmaceuticals Oy, the clinical stage biopharmaceutical company, today announces positive feedback from the MATINS study data monitoring committee following a comprehensive...
RNS Number: 6962 H Faron Pharmaceuticals Oy 26 March 2020 Faron Pharmaceuticals Oy. Correction to Faron´s Annual Report 2019. TURKU- FINLAND- Faron Pharmaceuticals Oy, the clinical stage biopharmaceutical company, announces the correction to the Annual Report 2019 which has been published yesterday..
RNS Number: 5169 H Faron Pharmaceuticals Oy 25 March 2020 Faron Pharmaceuticals Oy. Faron´s Annual Report 2019 published. TURKU- FINLAND- Faron Pharmaceuticals Oy, the clinical stage biopharmaceutical company, announces that its Annual Report for the year 2019 has been published today..
Faron Pharma 390p £169m (FARN.L) FY Dec 19 results. Part I of the open label phase I/II MATINS trial, initiated across multiple sites through Europe and primarily intended to investigate safety and tolerability, was completed with dose escalation reaching its planned maximum level of 10mg/kg. Clevegen demonstrated good tolerability at all dosing levels (0.1 to 10 mg/kg) without dose limiting toxicity. The US Food and Drug Administration (FDA) approved Faron's Investigational New Drug (IND) application for Clevegen, enabling expansion of the MATINS trial into the US. The Company envisages that further Traumakine trials are likely to be funded through a third party. The emergence of this novel virus, and the risk of ARDS among infected patients, is a reminder of the need for new treatments to tackle this potentially fatal condition. In March 2020, Faron announced it had acquired rights for the potential new use of AOC3 inhibitors covered by a recently filed patent application. Eur 13.3m loss. Cash EUR 7.1m. #FARN
RNS Number: 0049 H Faron Pharmaceuticals Oy 20 March 2020 NOTICE OF faron pharmaceuticals LTD's ANNUAL GENERAL MEETING. Company announcement, 20 March 2020 at 1.30 PM. Shareholders of Faron Pharmaceuticals Ltd are notified of the annual general meeting to be held on 15 April 2020 at 2:00 p.m. at the BioCity building, meeting room Manu at Tykistökatu 6, 20520...
Faron Pharmaceuticals Oy #FARN Announced, in its final results for the year ended January 1 to December 31, 2019, that its operating loss stood at €13.1 million, compared to €20.0 million in the previous year. Loss after tax was €13.3 million compared to €20.1 million in the prior year. The company’s diluted loss per share was 0.3c, compared to a loss of 0.7c in the prior year.
Financial statement release, Turku, 20 March 2019 at 9.00 AM. TURKU, FINLAND- Faron Pharmaceuticals Oy, the clinical stage biopharmaceutical company, today reports its financial statements for the year ended 31 December 2019 and H2 2019.. •Part I of the open label phase I/II MATINS trial, initiated across multiple sites through Europe and primarily intended to...
RNS Number: 8714 G Faron Pharmaceuticals Oy 19 March 2020. A second and final Price Monitoring Extension has been activated in this security. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom.
RNS Number: 8648 G Faron Pharmaceuticals Oy 19 March 2020. The auction call period has been extended in this security by 5 minutes. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom.
RNS Number: 0045 G Faron Pharmaceuticals Oy 12 March 2020. A second and final Price Monitoring Extension has been activated in this security. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom.
RNS Number: 9921 F Faron Pharmaceuticals Oy 12 March 2020. The auction call period has been extended in this security by 5 minutes. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom.
Faron Pharmaceuticals Oy #FARN Announced that the U.S. Food and Drug Administration (FDA) has accepted the proposed protocol design for the next Traumakine study in ARDS patients, following the company's protocol submission announced on 6 February 2020. The trial protocol reflects the feedback and conclusions from the FDA that further studies with interferon-beta (IFN beta-1a) should exclude the use of concomitant glucocorticoids since they are likely to block the desired therapeutic effect of Traumakine and may have a potentially deleterious impact on patient survival.
RNS Number: 3588 F Faron Pharmaceuticals Oy 09 March 2020 Faron Pharmaceuticals Oy. FDA accepts protocol for new Traumakine trial in ARDS. TURKU- FINLAND- Faron Pharmaceuticals Oy, the clinical stage biopharmaceutical company, today announces that the U.S. Food and Drug Administration has accepted the proposed protocol design for the next Traumakine study in...
Faron Pharmaceuticals Oy (FARN.L) Announced that in the ongoing dose finding part of the MATINS trial (Part I) a partial response has been identified in target lesions of a melanoma patient who has previously been heavily treated with immuno-oncology and chemo therapies. According to Response Evaluation Criteria in Solid Tumors (RECIST), a partial response in target lesion is defined as a decrease of greater than 30% in that same lesion. The patient had previously been treated with three different immune checkpoint inhibitors (pembrolizumab alone and ipililumab/nivolumab combination therapy) and had been on dabrafenib/trametinib anti-cancer treatment (BRAF-MEK inhibition) until December 2019. Data showed that the size of the target lesion tumour (a lung metastasis) reduced by 44% and other non- target lesions stabilized. Biochemical tumour load marker also declined and clearance of pleura fluid was observed. The patient had received two doses of Clevegen at 1 mg/kg with 3-week interval. #FARN
RNS Number: 0599 F Faron Pharmaceuticals Oy 05 March 2020 Faron Pharmaceuticals Oy. Second tumour regression identified, now in a melanoma patient. TURKU- FINLAND- Faron Pharmaceuticals Oy, the clinical stage biopharmaceutical company, announces that in the ongoing dose finding part of the MATINS trial a partial response has been identified in target lesions...
Faron Pharmaceuticals Oy #FARN Announced that it has acquired rights for the potential new use of AOC3 inhibitors covered by a recently filed patent application. Being expressed by many inflamed vascular endothelial cells, the AOC3 overexpression has been connected with many vascular diseases. The invention has been discovered by company’s scientific network (Inventors). Under the terms of the agreement, in consideration for assignment of the invention to the company, the inventors are eligible to receive low single digit royalties of net revenues of products associated with the invention and a low single digit percentage of payments to the company in the event of a third party license being entered into in respect of the invention.
Bid
-
-
-
Ask
  • High
    -
  • OPEN
    -
  • VOL
    -
  • MKT CAP
    -m
  • LOW
    -
  • CLOSE
    -
  • AVG VOL
    -
  • SHARES IN ISSUE
    31.03M

Company Profile

Faron is a clinical stage biopharmaceutical company developing novel treatments for medical conditions with significant unmet needs.

Classification

Market Indices-

Locations

HQ
Joukahaisenkatu 6
Intelligate
Turku
20520
Watchlist